MyFinsight
Home
Blog
About
Proceeds from issuance of
series b redeemable...
$200,000K
Exercise of options into
common stock
$1,131K
Net cash provided by
(used in) financing...
$184,143K
Canceled cashflow
$16,988K
Net increase in cash
and cash...
$18,235K
Canceled cashflow
$165,908K
Issuance costs from the
private placement...
$16,908K
Principal payments for
financing leases
$80K
Maturities of short-term
investments
$12,600K
Net cash assumed in
the acquisition of...
-$6,464K
Acquired in-process
research and development...
-$132,957K
Stock-based compensation
expense
$17,381K
Prepaid expenses
-$10,360K
Non-cash lease expense
$770K
Accounts payable and
accrued liabilities
$247K
Other assets
-$138K
Depreciation and
amortization
$54K
Amortization of financing
lease right-of-use...
$1K
Net cash (used in)
provided by investing...
-$139,502K
Net cash used in
operating activities
-$26,406K
Canceled cashflow
$19,064K
Canceled cashflow
$161,908K
Purchases of short-term
investments
$158,560K
Net loss
-$186,243K
Purchases of property and
equipment
$6K
Accretion on marketable
securities
-$1,126K
Operating lease
liabilities
-$837K
Compensation and employee
benefits
-$108K
Back
Back
Cash Flow
Faeth Therapeutics, Inc. (FTH)
Faeth Therapeutics, Inc. (FTH)
source: myfinsight.com